BioCryst Pharmaceuticals Inc. (BCRX) Stock Price Up 2.3%
BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) rose 2.3% during trading on Monday . The stock traded as high as $4.57 and last traded at $4.43, with a volume of 355,054 shares trading hands. The stock had previously closed at $4.33.
BCRX has been the subject of several research analyst reports. Piper Jaffray Cos. upgraded shares of BioCryst Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the company from $5.00 to $8.00 in a research report on Friday, August 12th. JPMorgan Chase & Co. restated a “hold” rating on shares of BioCryst Pharmaceuticals in a research report on Friday, August 5th. HC Wainwright restated a “buy” rating on shares of BioCryst Pharmaceuticals in a research report on Friday, August 5th. Jefferies Group upped their price target on shares of BioCryst Pharmaceuticals from $2.00 to $3.00 and gave the company a “hold” rating in a research report on Friday, August 5th. Finally, FBR & Co restated a “buy” rating and issued a $6.00 price target on shares of BioCryst Pharmaceuticals in a research report on Wednesday, July 6th. Two analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $8.22.
The firm’s market cap is $327.97 million. The company has a 50-day moving average of $3.63 and a 200 day moving average of $3.14.
BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.04. The business had revenue of $4.80 million for the quarter, compared to analyst estimates of $3.92 million. The firm’s quarterly revenue was down 81.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.06 EPS. Equities research analysts forecast that BioCryst Pharmaceuticals Inc. will post ($1.03) earnings per share for the current year.
In related news, insider Thomas R. Staab II sold 14,577 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Tuesday, August 9th. The shares were sold at an average price of $4.43, for a total transaction of $64,576.11. Following the transaction, the insider now owns 130,051 shares of the company’s stock, valued at approximately $576,125.93. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Bros. Advisors Lp Baker sold 4,046,590 shares of BioCryst Pharmaceuticals stock in a transaction that occurred on Tuesday, August 16th. The stock was sold at an average price of $5.00, for a total transaction of $20,232,950.00. The disclosure for this sale can be found here.
A number of hedge funds and institutional investors have recently added to or reduced their stakes in BCRX. Schwab Charles Investment Management Inc. raised its position in BioCryst Pharmaceuticals by 8.2% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 265,970 shares of the biotechnology company’s stock valued at $2,745,000 after buying an additional 20,210 shares during the last quarter. Jennison Associates LLC raised its position in BioCryst Pharmaceuticals by 1.8% in the fourth quarter. Jennison Associates LLC now owns 1,348,563 shares of the biotechnology company’s stock valued at $13,917,000 after buying an additional 24,014 shares during the last quarter. Finally, Morgan Stanley raised its position in shares of BioCryst Pharmaceuticals by 13.9% in the fourth quarter. Morgan Stanley now owns 103,804 shares of the biotechnology company’s stock worth $1,071,000 after buying an additional 12,646 shares during the last quarter.
BioCryst Pharmaceuticals, Inc (BioCryst) is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. The Company uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.